ClinConnect ClinConnect Logo
Search / Trial NCT05572905

Effect of Acute Bout of Exercise on Levels of PAHSA

Launched by LENKA ROSSMEISLOVA · Oct 5, 2022

Trial Information

Current as of June 08, 2025

Unknown status

Keywords

Acute Exercise Adipose Tissue Insulin Sensitivity Pahsa Lipokinins

ClinConnect Summary

This clinical trial, called the Effect of Acute Bout of Exercise on Levels of PAHSA (ETAPA), is studying how exercise affects certain substances in the body that may help improve insulin sensitivity. Insulin sensitivity is important for preventing conditions like type 2 diabetes and heart disease, especially in people who are overweight or aging. Researchers want to understand how both short-term and long-term exercise can increase levels of a substance called PAHSA, which has been shown to help reduce inflammation and improve insulin function.

To participate, you need to be a healthy young adult or elderly person, and you should not have certain medical conditions or be taking specific medications that could interfere with the study. Participants will undergo some assessments, which may include blood draws and a small procedure to take a sample of fat from the abdomen. This study is currently looking for volunteers, and it aims to provide important insights that could lead to better treatments for metabolic disorders linked to obesity and aging.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • healthy young lean, young obese and elderly omnivorous men and women as defined by BMI, self-reported activity, self-reported medical history and self-reported diet assessment
  • must be able to withstand repeated blood draws
  • must be able to undergo abdominal fat biopsy
  • Exclusion Criteria:
  • use of betablockers
  • use of glucocorticoids
  • use of non-steroidal anti-inflammatory drugs
  • use of metformin in prediabetes
  • use of psychiatric drugs such as selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, anticonvulsants and others
  • oncologic malignancy
  • chronic inflammatory or autoimmune diseases
  • diabetes mellitus
  • chronic ischemic heart disease
  • cardiovascular and pulmonary disease
  • renal and hepatological disease as assessed per biochemistry
  • musculo-skeletal deviations limiting physical performance
  • substance abuse
  • other than omnivorous diet

About Lenka Rossmeislova

Lenka Rossmeislova is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a commitment to ethical standards and rigorous scientific methodologies, the organization collaborates with researchers, healthcare professionals, and regulatory bodies to design and execute clinical trials that address unmet medical needs. By fostering a culture of transparency and collaboration, Lenka Rossmeislova aims to contribute valuable insights to the medical community and facilitate the development of safe and effective treatments.

Locations

Prague, , Czechia

Patients applied

0 patients applied

Trial Officials

Lenka Rossmeislová, PhD

Principal Investigator

3rd Faculty of Medicine of Charles University in Prague

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials